^
Association details:
| Biomarker: | RET mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | EP0031 (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors.
Published date:
05/25/2023
Excerpt:
69 pts treated at the 40-120mg dose levels (57 NSCLC, 10 MTC, 1 pancreatic cancer, 1 ovarian cancer) were evaluable for efficacy analysis, ORR was 64% (NSCLC, MTC and pancreatic cancer)….KL590586 was well-tolerated, and associated with robust clinical activity in RET-altered tumors regardless of tumor type, including NSCLC pts with resistance to1st gen SRIs and with CNS mets.
DOI:
10.1200/JCO.2023.41.16_suppl.3007
Trial ID:
